Navigation Links
Cytogen Reports Publication Validating the Utility of its,Proprietary ProChart Database

ry mouth that is approved in the U.S. as a prescription medical device. QUADRAMET(R) (samarium Sm-153 lexidronam injection) is approved for the treatment of pain in patients whose cancer has spread to the bone. PROSTASCINT(R) (capromab pendetide) is a PSMA-targeting monoclonal antibody-based agent to image the extent and spread of prostate cancer and SOLTAMOX(TM) (tamoxifen citrate) is the first liquid hormonal therapy approved in the U.S. for the treatment of breast cancer in adjuvant and metastatic settings. The Company is also developing CYT-500, a third-generation radiolabeled antibody to treat prostate cancer. Cytogen's product-focused strategy centers on attaining sustainable growth through clinical, commercial, and strategic initiatives.

A copy of the full prescribing information for CAPHOSOL, QUADRAMET, PROSTASCINT and SOLTAMOX, including Boxed Warnings, warnings, precautions, adverse events and other safety information may be obtained in the U.S. from Cytogen Corporation by calling toll-free 800-833-3533 or by visiting the web site at http://www.cytogen.com. The Company's website is not part of this press release.

This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and investors are cautioned not to put any undue reliance on any forward-looking statement. There are a number of important factors that could cause Cytogen's results to differ materially from those indicated by such forward-looking statements. In particular, Cytogen's business is subject to a n
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
2. Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting
3. New Data for Cytogens QUADRAMET Reported at Annual ASCO Meeting
4. Preclinical Data on Cytogens Technology to be Reported at the AACR Annual Meeting
5. New Clinical Data for Cytogens Quadramet and Prostacint to be Reported at Upcoming Major Medical Meetings
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
10. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
11. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
Post Your Comments:
(Date:8/27/2014)... 27, 2014  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapies for the treatment ... management will be participating at the FBR Healthcare One ... Global Healthcare Conference.  Details of the two events are ... Conference Date: Wednesday September 3 rd Location: ...
(Date:8/26/2014)...  Kewaunee Scientific Corporation (Nasdaq: KEQU ) ... 31, 2014. Sales for the quarter were ... first quarter last year. Net earnings for the quarter ... to net earnings of $1,587,000, or $0.61 per diluted ... However, both sales and earnings in the first quarter ...
(Date:8/26/2014)... , Aug. 26, 2014  Actavis plc (NYSE: ... that Brenton Saunders , CEO and President of Actavis, ... at the Morgan Stanley Global Healthcare Conference 2014 in ... http://photos.prnewswire.com/prnh/20130124/NY47381LOGO The presentation will take place ... at the Grand Hyatt New York, 109 East 42 nd ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events 2AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events 3Kewaunee Scientific Reports Results for First Quarter 2Kewaunee Scientific Reports Results for First Quarter 3Kewaunee Scientific Reports Results for First Quarter 4Kewaunee Scientific Reports Results for First Quarter 5Kewaunee Scientific Reports Results for First Quarter 6Actavis to Present at Morgan Stanley Global Healthcare Conference 2014 2
... , POTOMAC, Md., Nov. 24 In ... has added Philadelphia jurors to her Thanksgiving gratitude list. ... I am so thankful to them," she said of Monday,s ... , Wisneski is among 12,000 women nationwide who have sued ...
... , , HOLMDEL, ... TrackWise software and the market leader in enterprise quality and ... expanding consumer product company and the parent company for globally ... with TrackWise Enterprise Quality Management System (EQMS). The company is ...
Cached Medicine Technology:Maryland Woman Thankful for Wyeth Verdicts 2SSL International plc Embraces TrackWise(R) Software for Global Quality and Compliance Efforts 2SSL International plc Embraces TrackWise(R) Software for Global Quality and Compliance Efforts 3
(Date:8/27/2014)... 2014 (HealthDay News) -- A new genetic discovery about ... the bowel disorder, researchers report. The scientists ... how their genes work, and said these changes can ... the possibility of a simple diagnostic test for Crohn,s, ... develops and suggest possible gene targets for new treatments, ...
(Date:8/27/2014)... August, 27, 2014) An experimental drug designed to help ... first treatment for anemia of inflammation, according to results from ... online today in Blood , the Journal ... is a condition that occurs when red blood cells are ... individual has anemia, the body does not get enough oxygen, ...
(Date:8/27/2014)... tested an advanced statistical model to evaluate the ... as published yesterday in Human Genetics . ... in current analyses. Complex diseases like cancer usually ... factors. When many such combinations are studied, identifying ... combinations among affected individuals becomes difficult. In this ...
(Date:8/27/2014)... 2014 The Global and China Maleic ... the current state of the Maleic Anhydride industry in ... overview of the industry, including definitions, applications and industry ... analysis are provided with a focus on history, developments, ... between the international and Chinese situation is also offered. ...
(Date:8/27/2014)... Sugar Manufacturing in Australia ... in global supply and demand, which have contributed to ... industry derives a large share of its revenue from ... dynamics, with supply and prices being determined by larger ... Australian dollar for the majority of the past five ...
Breaking Medicine News(10 mins):Health News:Scientists Spot Genetic Clues to Crohn's Disease 2Health News:Drug represents first potential treatment for common anemia 2Health News:Dartmouth isolates environmental influences in genome-wide association studies 2Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 2Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 3Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 4Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 5Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4
... the Staying Sharp session on October 4 at the Embassy ... Part of a highly recognized series, the program will emphasize ... industry; factors that predict future cognitive function; and the importance ... The public can reserve free tickets through the toll-free line: ...
... articulating wall mounted arms that offer a space-saving solution without ... environment. , ... Ferndale, MI (PRWEB) ... the next generation in articulating wall-mounted arms. Offering 270 degrees ...
... Oct. 1 Sysmex America, Inc. and its,subsidiary, ... the,company,s new brand logo, said Kazuya Obe, Executive ... The timing of this brand change,corresponds with the ... and,the company,s 40th anniversary. The new logo marks ...
... with,solutions and recommendations drawing on experience working ... PLYMOUTH MEETING, Pa., Oct. 1 Anticipating,the ... Safety and Quality,Improvement Act of 2005, ECRI ... to improve patient care, will preview its ...
... Researchers at the Farber Institute for Neurosciences ... Psychiatry and Human Behavior at Jefferson Medical College ... $3.7 million grant from The National Eye Institute ... macular degeneration (AMD). Barry W. Rovner, M.D., ...
... Rise of cities, risky behavior in west central Africa between ... 1 (HealthDay News) -- The most pervasive global strain of ... a new study claims. , The research, which is ... that HIV began spreading between 1884 and 1924, around the ...
Cached Medicine News:Health News:Enovate IT Announces Fluid - a New Movement in Wall Arms 2Health News:Sysmex Announces Brand Change 2Health News:ECRI Institute Unveils Comprehensive Patient Safety Organization (PSO) Services 2Health News:ECRI Institute Unveils Comprehensive Patient Safety Organization (PSO) Services 3Health News:Jefferson awarded multi-million dollar grant from National Eye Institute for new clinical trial 2Health News:HIV Outbreak Began Decades Earlier Than Thought 2
TSH EIA Thyroid Function 025-BC-1001...
... The anti-TG test kit is a ... microplate format. It is designed for the ... thyroglobulin (TG) in serum or plasma. The ... 1: Calibrators, controls and patient samples are ...
Free Estriol (E3) RIA Reproductive Hormones 024-IDC-1000...
FSH EIA Reproductive Markers 025-BC-1029 Follicle Stimulating Hormone...
Medicine Products: